购物车
- 全部删除
- 您的购物车当前为空
Evixapodlin (PD-1/PD-L1-IN 7) 是一种人 PD-1/PD-L1蛋白/蛋白相互作用抑制剂(IC50:0.213)。Evixapodlin 具有抗癌和抗病毒活性。
为众多的药物研发团队赋能,
让新药发现更简单!
Evixapodlin (PD-1/PD-L1-IN 7) 是一种人 PD-1/PD-L1蛋白/蛋白相互作用抑制剂(IC50:0.213)。Evixapodlin 具有抗癌和抗病毒活性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 987 | 现货 | |
5 mg | ¥ 2,530 | 现货 | |
10 mg | ¥ 3,960 | 现货 | |
25 mg | ¥ 7,630 | 现货 | |
50 mg | ¥ 9,870 | 现货 | |
100 mg | ¥ 13,800 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 3,580 | 现货 |
产品描述 | Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities. |
靶点活性 | PD-1/PD-L1 (human):0.213 nM (IC50) |
体外活性 | Evixapodlin exhibits an ability to increase the production of IFN-γ and Granzyme B in both CD8+ and CD4+ T cells in individuals with chronic hepatitis B (CHB). Additionally, Evixapodlin enhances the frequency of Granzyme B-positive cells among HBV-specific CD8+ and CD4+ T cells.[1] |
体内活性 | Evixapodlin (10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment results in over 90% occupancy of the PD-L1 target on tumor cells. Evixapodlin effectively suppresses tumor growth in a mouse colorectal tumor model (MC38) that expresses human PD-L1.[1] |
别名 | PD-1/PD-L1-IN 7, GS-4224 |
分子量 | 691.61 |
分子式 | C34H36Cl2N8O4 |
CAS No. | 2374856-75-2 |
Smiles | COc1nc(cnc1CNC[C@@H]1CCC(=O)N1)-c1cccc(c1Cl)-c1cccc(c1Cl)-c1cnc(CNC[C@@H]2CCC(=O)N2)c(OC)n1 |
密度 | 1.310 g/cm3 (Predicted) |
存储 | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 45.0 mg/mL (65.1 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容